As Chief Medical Officer, Asher Schachter oversees early phase clinical research and development for Visterra’s clinical biologic assets, spanning a broad therapeutic spectrum including nephrology, rheumatology/autoimmune diseases, transplant immunology and neurodegenerative diseases, aiming to de-risk assets through clinical PoC and transition to late phase development in cooperation with Otsuka partners.
Asher joined Visterra in 2020 as VP, Translational Medicine. Prior to moving to industry, Asher practiced clinical pediatric nephrology at Boston Children’s Hospital. During his time there, he conducted translational research on focal segmental glomerulosclerosis (FSGS) and transplant immunology biomarkers. Subsequently, Asher joined the Translational Medicine department at the Novartis Institutes for BioMedical Research as the medical lead on early clinical development programs. He then joined CAMP4 Therapeutics as Translational Medicine lead covering several disease areas.
Asher received his MD from the University of Toronto, completed his pediatric residency at Toronto’s Hospital for Sick Children, and his pediatric nephrology fellowship at Boston Children’s Hospital. Asher received his MMSc (Medical Science), and MSc (Medical Informatics) from the Harvard-MIT Division of Health Sciences and Technology. Subsequently, Asher was a Sloan Industry Center fellow at MIT where he furthered his thesis work building a Bayesian network model of success in drug development.
